| Name | Title | Contact Details |
|---|
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
Caldera Pharmaceuticals is a Los Alamos, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vista del Mar Hospital offers adolescent & adult inpatient psychiatric care, adult detox/dual diagnosis and partial hospitalization programs.
Rising Pharmaceuticals is an industry leader in marketing and distributing innovative branded and multi-source prescription and over-the-counter pharmaceutical products.
RESTAT is a West Bend, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.